166 related articles for article (PubMed ID: 25503779)
1. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
de Cremoux P; Dalvai M; N'Doye O; Moutahir F; Rolland G; Chouchane-Mlik O; Assayag F; Lehmann-Che J; Kraus-Berthie L; Nicolas A; Lockhart BP; Marangoni E; de Thé H; Depil S; Bystricky K; Decaudin D
Breast Cancer Res Treat; 2015 Jan; 149(1):81-9. PubMed ID: 25503779
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.
Stark K; Burger A; Wu J; Shelton P; Polin L; Li J
PLoS One; 2013; 8(9):e74525. PubMed ID: 24058584
[TBL] [Abstract][Full Text] [Related]
3. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
4. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
5. Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition.
Sulaiman A; Sulaiman B; Khouri L; McGarry S; Nessim C; Arnaout A; Li X; Addison C; Dimitroulakos J; Wang L
FEBS Lett; 2016 Dec; 590(24):4606-4616. PubMed ID: 27859250
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
Salahuddin A; Ghanem H; Omran GA; Helmy MW
Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
[TBL] [Abstract][Full Text] [Related]
7. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
11. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
13. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
[TBL] [Abstract][Full Text] [Related]
14. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
16. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
[TBL] [Abstract][Full Text] [Related]
17. The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype.
Fortunati N; Marano F; Bandino A; Frairia R; Catalano MG; Boccuzzi G
Int J Oncol; 2014 Mar; 44(3):700-8. PubMed ID: 24366407
[TBL] [Abstract][Full Text] [Related]
18. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
20. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
